En­tact Bio makes its Se­ries A de­but with $81M to launch pro­tein en­hance­ment plat­form

En­tact Bio has se­cured $81 mil­lion in a Se­ries A round to push for­ward its plat­form for de­vel­op­ing ther­a­pies that can en­hance the func­tion of pro­teins that are cru­cial to fight dis­ease.

Known as en­hance­ment-tar­get­ing chimeric (EN­TAC) mol­e­cules, En­tact’s idea is to use the drug plat­form in the treat­ment of cer­tain can­cers, in­flam­ma­to­ry dis­eases and rare ge­net­ic dis­or­ders as­so­ci­at­ed with hap­loin­suf­fi­ciences, in which pa­tients have too lit­tle of a pro­tein in their cells. Be­cause EN­TACs are small mol­e­cules, they can be oral­ly de­liv­ered and are much cheap­er to man­u­fac­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER